MX2023001153A - Composiciones y metodos de uso de los activadores del canal kv7. - Google Patents

Composiciones y metodos de uso de los activadores del canal kv7.

Info

Publication number
MX2023001153A
MX2023001153A MX2023001153A MX2023001153A MX2023001153A MX 2023001153 A MX2023001153 A MX 2023001153A MX 2023001153 A MX2023001153 A MX 2023001153A MX 2023001153 A MX2023001153 A MX 2023001153A MX 2023001153 A MX2023001153 A MX 2023001153A
Authority
MX
Mexico
Prior art keywords
methods
channel activators
compounds
pharmaceutical compositions
compositions
Prior art date
Application number
MX2023001153A
Other languages
English (en)
Inventor
Charles A Flentge
Michael E Bozik
Scott S Harried
Lynn Resnick
George T Topalov
Justin K Belardi
David A Mareska
James S Hale
Original Assignee
Knopp Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knopp Biosciences Llc filed Critical Knopp Biosciences Llc
Publication of MX2023001153A publication Critical patent/MX2023001153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan benzoimidazol-1,2-il amidas opcionalmente sustituidas, composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva de dichos compuestos y un excipiente farmacéuticamente aceptable, y métodos para tratar enfermedades asociadas a Kv7, tales como epilepsia, esclerosis lateral amiotrófica, varios tipos de dolor, hiperexcitabilidad, discinesia, distonía, manía y tinnitus con tales compuestos y composiciones farmacéuticas.
MX2023001153A 2018-03-19 2020-09-17 Composiciones y metodos de uso de los activadores del canal kv7. MX2023001153A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862644932P 2018-03-19 2018-03-19
US201862644902P 2018-03-19 2018-03-19
US201862663438P 2018-04-27 2018-04-27
US201862697198P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
MX2023001153A true MX2023001153A (es) 2023-02-22

Family

ID=67905138

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009693A MX2020009693A (es) 2018-03-19 2019-03-19 Composiciones y metodos de uso de los activadores del canal kv7.
MX2023001153A MX2023001153A (es) 2018-03-19 2020-09-17 Composiciones y metodos de uso de los activadores del canal kv7.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020009693A MX2020009693A (es) 2018-03-19 2019-03-19 Composiciones y metodos de uso de los activadores del canal kv7.

Country Status (13)

Country Link
US (4) US10851067B2 (es)
EP (1) EP3768677A4 (es)
JP (2) JP2021518844A (es)
KR (1) KR20200133259A (es)
CN (1) CN112771039A (es)
AU (3) AU2019239955B2 (es)
BR (1) BR112020018933A2 (es)
CA (1) CA3093976A1 (es)
IL (2) IL277419B2 (es)
MX (2) MX2020009693A (es)
NZ (1) NZ767228A (es)
SG (1) SG11202008030WA (es)
WO (1) WO2019183148A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481653B2 (en) * 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
BR112020018933A2 (pt) * 2018-03-19 2020-12-29 Knopp Biosciences Llc Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
CN114728961A (zh) * 2019-09-17 2022-07-08 诺普生物科学有限责任公司 Kv7通道激活剂的使用方法
WO2024050389A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators and nmda receptor antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
JPH0772181A (ja) 1993-09-03 1995-03-17 Advantest Corp 電位波形測定方法および装置
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2607219A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
WO2009022746A1 (ja) 2007-08-10 2009-02-19 Nippon Soda Co., Ltd. 含窒素複素環化合物および有害生物防除剤
TWI482768B (zh) 2007-11-22 2015-05-01 Zenyaku Kogyo Kk 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
US20110269783A1 (en) 2008-11-10 2011-11-03 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
RU2525116C2 (ru) 2008-12-19 2014-08-10 Дженентек, Инк. Гетероциклические соединения и способы применения
CN102971307A (zh) 2010-07-08 2013-03-13 辉瑞大药厂 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
ES2885424T3 (es) * 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7
WO2015023958A1 (en) * 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
US9481653B2 (en) * 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
BR112020018933A2 (pt) * 2018-03-19 2020-12-29 Knopp Biosciences Llc Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
CN114728961A (zh) * 2019-09-17 2022-07-08 诺普生物科学有限责任公司 Kv7通道激活剂的使用方法

Also Published As

Publication number Publication date
US11261162B2 (en) 2022-03-01
US11724990B2 (en) 2023-08-15
BR112020018933A2 (pt) 2020-12-29
NZ767228A (en) 2023-11-24
SG11202008030WA (en) 2020-10-29
IL310136A (en) 2024-03-01
AU2023266373B2 (en) 2024-02-08
MX2020009693A (es) 2021-01-08
AU2019239955B2 (en) 2023-08-24
CN112771039A (zh) 2021-05-07
AU2023266373A1 (en) 2023-12-07
AU2019239955A1 (en) 2020-10-01
US10851067B2 (en) 2020-12-01
US20230000831A1 (en) 2023-01-05
US20240002349A1 (en) 2024-01-04
AU2024202496A1 (en) 2024-05-09
CA3093976A1 (en) 2019-09-26
EP3768677A1 (en) 2021-01-27
IL277419B1 (en) 2024-03-01
IL277419B2 (en) 2024-07-01
IL277419A (en) 2020-11-30
US20210130299A1 (en) 2021-05-06
EP3768677A4 (en) 2021-12-22
JP2024026104A (ja) 2024-02-28
JP2021518844A (ja) 2021-08-05
WO2019183148A1 (en) 2019-09-26
KR20200133259A (ko) 2020-11-26
US20190284142A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
MX2023001153A (es) Composiciones y metodos de uso de los activadores del canal kv7.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2018005256A (es) Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
MX2023001741A (es) Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2020002884A (es) Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
MX2019008875A (es) Composiciones de inhibidor del canal crac.
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
MX2023011326A (es) Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
PH12020551527A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2021008188A (es) Compuestos de anandamida.
WO2019067768A3 (en) FIXED DOSE COMBINATION FORMULATIONS FOR THE TREATMENT OF PAIN
MX2018000963A (es) Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol.
MX2019008847A (es) Profarmacos de cisteamina.